Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J, Basilea To Base Ceftobiprole Filing For Hospital-Acquired Pneumonia On Phase III Results

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite positive results in patients with hospital-acquired pneumonia, the Phase III study failed to demonstrate non-inferiority in a high-risk subgroup.

You may also be interested in...



J&J/Basilea’s Ceftobiprole NDA Edges Ahead

“Approvable” word from FDA represents a victory in tough antibiotic field.

J&J/Basilea’s Ceftobiprole NDA Edges Ahead

“Approvable” word from FDA represents a victory in tough antibiotic field.

FDA Wants More Ceftobiprole Data From J&J/Basilea

Racing against Theravance's "approvable" telavancin, company will supply added results in diabetic foot infections.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel